Skip to main content

Beneficial ownership — 13D / 13G

87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Yaletown Bros Ventures Ltd. BRSH Bruush Oral Care Inc. Common Stock 13D/A 42.6% 2y
Wavetech Helium, Inc. BSIN Big Sky Industrial Inc. 13G 9.3% 2y
Griffith Curtis C SPFI South Plains Financial, Inc. 13G/A 11.56% 2y
Blue Star Exploration Company CRK Comstock Resources Inc 13D/A 69.4% 2y
Mink Brook Asset Management LLC ACU Acme United Corp 13G 5.54% 2y
GAMCO INVESTORS, INC. ET AL INVX Innovex International, Inc. 13D/A 6.55% 2y
PERCEPTIVE ADVISORS LLC LYRA Lyra Therapeutics, Inc. 13D/A 19.5% 2y
Michael A. Davis (“Davis”) CYAN Cyanotech Corp 13D/A 21.7% 2y
GAMCO INVESTORS, INC. ET AL BELFA Bel Fuse Inc 13D/A 9% 2y
Joe Thomas DTCX Datacentrex, Inc. 13G/A 9.84% 2y
GIC Private Ltd IQV Iqvia Holdings Inc. 13G 5.01% 2y
Abdiel Qualified Master Fund, LP APPN Appian Corp 13D/A 22.8% 2y
ORBIMED ADVISORS LLC SCPH scPharmaceuticals Inc. Common Stock 13D/A 12.1% 2y
Pacific Investment Management Company LLC QMCO Quantum Corp 13D/A 21.76% 2y
ORBIMED ADVISORS LLC APLM Apollomics Inc. 13D/A 0.05% 2y
Karpus Management, Inc. NEA Nuveen AMT-Free Quality Municipal Income Fund 13D/A 7.4% 2y
Engaged Capital LLC PTLO Portillo's Inc. 13D 9.9% 2y
S.H.N. Financial Investments Ltd. XPON Expion Energy, Inc. 13G 9.9% 2y
L1 Capital Global Opportunities Master Fund, Ltd. XPON Expion Energy, Inc. 13G 9.9% 2y
Stonepine Capital Management, LLC TENX Tenax Therapeutics, Inc. 13G 9.99% 2y
GREAT POINT PARTNERS LLC ELEV Elevation Oncology, Inc. Common stock 13G 6.56% 2y
Mudrick Capital Management, L.P. MARK Remark Holdings, Inc. 13G 9.99% 2y
WealthTrust Axiom LLC EPM Evolution Petroleum Corp 13G 5.04% 2y
Xin Rong Gan CD Chaince Digital Holdings Inc. 13D/A 7.6% 2y
Hailei Zhang CD Chaince Digital Holdings Inc. 13G/A 3.7% 2y
Hanqi Li CD Chaince Digital Holdings Inc. 13D/A 8.6% 2y
Hong Mei Zhou CD Chaince Digital Holdings Inc. 13D/A 7.6% 2y
JACOB SAFIER TTOO T2 Biosystems, Inc 13G/A 4.3% 2y
Safier Jacob TTOO T2 Biosystems, Inc 13G/A 4.3% 2y
TIGER GLOBAL MANAGEMENT LLC OKLO Oklo Inc. 13G/A 2.5% 2y
GAMCO INVESTORS, INC. ET AL INVX Innovex International, Inc. 13D/A 6.55% 2y
BML Investment Partners, L.P. ANTX AN2 Therapeutics, Inc. 13G/A 19.3% 2y
BML Investment Partners, L.P. TLIS Talis Biomedical Corporation Common Stock 13G/A 11.2% 2y
EW Healthcare Partners, L.P. VERO Venus Concept Inc. 13D/A 45.8% 2y
Edward Smolyansky LWAY Lifeway Foods, Inc. 13D/A 21.5% 2y
Saba Capital Management, L.P. IIF Morgan Stanley India Investment Fund, Inc. 13D 5.12% 2y
Riot Platforms, Inc. KEEL Keel Infrastructure Corp. 13D/A 18.9% 2y
Shoshana Shendelman APLT Applied Therapeutics, Inc. Common Stock 13D/A 6.6% 2y
James Lim STEP StepStone Group Inc. 13D/A 8.3% 2y
WP Triton Co-Invest, L.P. VSAT Viasat Inc 13D/A 6.57% 2y
Jeffrey Allen Morris PVCT Provectus Biopharmaceuticals, Inc. 13G 11.3% 2y
Archon Capital Management LLC STIM Neuronetics, Inc. 13G/A 3% 2y
325 CAPITAL LLC APEI American Public Education Inc 13D/A 10.8% 2y
Growth Equity Opportunities 17, LLC SVRA Savara Inc 13D/A 14.9% 2y
GKCC, LLC ELTX Elicio Therapeutics, Inc. 13D/A 38.7% 2y
MFN Partners, LP RXO RXO, Inc. 13G/A 19.9% 2y
ONTARIO TEACHERS PENSION PLAN BOARD VSAT Viasat Inc 13D/A 6.69% 2y
PERCEPTIVE ADVISORS LLC MGTX MeiraGTx Holdings plc 13D/A 16.4% 2y
Mount Grey Partners LP CLST Catalyst Bancorp, Inc. 13G/A 0% 2y
Todd Deutsch AIM AIM ImmunoTech Inc. 13D/A 3% 2y